What worries me is that although Epanova is late to the party and perhaps an inferior product, they might be able to pass Vascepa in sales simply because they have a superior company (Sales Reps) and other resources to market their product. I don't mind waiting until after Dec 20th, but shortly there after, VASCEPA needs to be in the hands of a reputable BIG PHARM. Otherwise, we could be sitting sub $10.00 for a very long time. Perhaps forever.....